A step towards treating KRAS-mutant NSCLC
- PMID: 23200176
- DOI: 10.1016/S1470-2045(12)70528-4
A step towards treating KRAS-mutant NSCLC
Comment on
-
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.Lancet Oncol. 2013 Jan;14(1):38-47. doi: 10.1016/S1470-2045(12)70489-8. Epub 2012 Nov 28. Lancet Oncol. 2013. PMID: 23200175 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous